Physician profile
Won H Park
NPI 1932337896
$4,208.73
in general payments reported to CMS, 2019-2025
28 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $760 · 2021: $1,276 · 2022: $430 · 2023: $203 · 2024: $201 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,180.63 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $471.57 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $322.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $253.42 | 2019-2024 | Airsupra |
| Allergan, INC. | $220.66 | 2019-2020 | |
| Abbott Laboratories | $216.57 | 2019-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $193.41 | 2023-2025 | Signia, Intellis Adaptivestim, Vanta Adaptivestim |
| Abbvie INC. | $178.74 | 2019-2022 | |
| Atricure, INC. | $155.74 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Biohaven Pharmaceutical Holding Company LTD. | $145.99 | 2022 | |
| Esperion Therapeutics, INC. | $140.89 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $84.13 | 2022-2025 | Rexulti |
| Amgen INC. | $83.82 | 2020 | |
| Amarin Pharma, INC. | $76.19 | 2019-2021 | |
| Astellas Pharma US INC | $69.50 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $49.75 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $45.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $40.66 | 2019-2020 | |
| Pfizer INC. | $38.10 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $30.46 | 2021 | |
| Merck Sharp & Dohme LLC | $24.99 | 2019 | |
| Inspire Medical Systems, INC. | $24.56 | 2025 | Inspire |
| Avanir Pharmaceuticals, INC. | $22.89 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.55 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.89 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Won Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.